Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium
January 24 2020 - 7:30AM
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in
developing novel, controllable cellular immunotherapies for
cancers, today presented new Phase 1 translational results for
BPX-601 at the American Society of Clinical Oncology
Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco. The
poster titled “Tumor Infiltration and Cytokine Biomarkers of
Prostate Stem Cell Antigen (PSCA)-Directed GoCAR-T Cells in
Patients with Advanced Pancreatic Tumors” presented new data from a
cohort treated with BPX-601 and a single dose of rimiducid that
showed immunomodulation in both the periphery and tumor
microenvironment and provided additional insights into surrogate
biomarkers of iMC-mediated GoCAR-T® activity.
“These translational results further support the potential for
BPX-601 and for our GoCAR™ platform in solid tumors,” stated Rick
Fair, President and Chief Executive Officer, Bellicum
Pharmaceuticals. “We are particularly encouraged by the findings of
tumor infiltration and GoCAR-T mediated immunomodulation. We will
look to build on these markers of activity in the next cohort of
the study, which will evaluate repeat rimiducid dosing to
reactivate BPX-601 cells over time. Initial results from this
Cohort 5C are expected during the second half of this year.”
The poster at ASCO GI presented data from Cohort 5B of the
study, consisting of 5 pancreatic cancer patients treated with
BPX-601 and a single dose of rimiducid. The primary observations
were:
- BPX-601 GoCAR-T cells exhibited enhanced survival and
persistence up to 9 months.
- Activation of BPX-601 GoCAR-T cells mediated upregulation of
immunomodulatory cytokines in patients.
- BPX-601 GoCAR-T cells infiltrated metastatic pancreatic
tumors.
- Changes in tumor microenvironment gene expression consistent
with a productive CAR-T cell immune response were observed in
patients treated with BPX-601 GoCAR-T cells activated by
rimiducid.
Interim clinical results from the trial—including results from
cohort 5B—were reported at ASCO on June 1, 2019 and may be found on
the Bellicum website under Scientific Publications.
About BPX-601
BPX-601, the company’s first GoCAR-T® product candidate,
incorporates iMC, Bellicum’s inducible co-activation domain. iMC
(inducible MyD88/CD40) is designed to provide a powerful boost to T
cell proliferation and persistence, production of immunomodulatory
cytokines and enable the CAR-T to override key immune inhibitory
mechanisms, including PD-1 and TGF-beta. BPX-601 is being evaluated
as a treatment for pancreatic tumors expressing prostate stem cell
antigen (PSCA).
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving
to deliver cures through controllable cell therapies. The company’s
next-generation product candidates are differentiated by powerful
cell signaling technologies designed to produce more effective
CAR-T and allogeneic cell therapies. Bellicum’s lead GoCAR-T®
candidate, BPX-601, is designed to be a more efficacious CAR-T cell
product capable of overriding key immune inhibitory mechanisms.
More information about Bellicum can be found at www.bellicum.com.
Forward-Looking Statement
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Bellicum may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “designed,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the potential of BPX-601 in the treatment of
pancreatic cancer, the relevance of translational data to
prediction of clinical activity, and the potential of the GoCAR
platform for the treatment of solid tumors, and whether further
clinical trials of any GoCAR-enabled construct will produce
favorable results. Various factors may cause differences between
Bellicum’s expectations and actual results as discussed in greater
detail under the heading “Risk Factors” in Bellicum’s filings with
the Securities and Exchange Commission, including without
limitation our quarterly report on Form 10-Q for the three months
ended September 30, 2019 and our annual report on Form 10-K
the year ended December 31, 2018. Any forward-looking
statements that Bellicum makes in this press release speak only as
of the date of this press release. Bellicum assumes no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Source: Bellicum Pharmaceuticals
Investors:Robert H. Uhl Managing Director Westwicke IR
858-356-5932 Robert.uhl@westwicke.com
Media: Kate Coyle Senior Vice President Westwicke PR
203-682-8210 kate.coyle@icrinc.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2024 to May 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From May 2023 to May 2024